Jan Mičan

This paper designs next-generation thrombolytic proteases with improved catalytic efficiency, fibrin selectivity, and inhibition resistance through multi-objective enzyme engineering.

The paper compares biochemical and immunological properties of engineered low-immunogenic staphylokinase variants to identify the most promising for thrombolytic therapy.

ProtXAI combines molecular dynamics and explainable AI to identify residue-level determinants of protein conformational changes across diverse systems.

This study investigates the conformational flexibility of staphylokinase variants to explain their reduced immunogenicity and altered properties.